Biomedical subjects

J Bonneterre

Publications and source records attributed to J Bonneterre.

167 records · Page 10Linked to original sources

PubMedDate not supplied

Stimulation of DNA synthesis by prolactin in human breast tumor explants. Relation to prolactin receptors.

Breast-cancer tissue from 38 patients was tested for prolactin sensitivity by measuring both 16-hour (3H)dT incorporation in tissue fragments during 24-hour organ cultures, and prolactin receptors in tumor specimens. We observed a stimulation of DNA synthesis by prolactin in 6/38 (16%) cases; the stimulation was maximum with physiological concentrations of prolactin (0.05 to 0.2 microgram/ml medium). The stimulation of DNA synthesis never occurred in the absence of prolactin receptors. There is no relation between the response to prolactin and estradiol or progesterone receptor levels, but in four cases the stimulation was observed when the three receptors were present. Finally, the response to the stimulation was independent of the clinical stage of the patient.

Breast Neoplasms↗

PubMedDate not supplied

[Genetics and cancers].

Explore the source record for details and available documents.

Genetic Diseases, Inborn↗

PubMedDate not supplied

Urinary excretion of deoxypyridinoline in patients with breast cancer.

Deoxypyridinoline (Dpyr), a crosslink of collagen molecules found in bone and excreted in urine during bone degradation, was measured in patients with breast cancer. Four groups of patients included, 42 premenopausal (32 without and 10 with bone metastases) and 65 postmenopausal (39 without and 26 with bone metastases) women. For comparison, 21 healthy women were studied. Dpyr was measured in urine samples using an enzyme immunoassay. Breast cancer patients showed elevated levels of Dpyr, irrespective of whether or not they had bone metastases. Dpyr excretion was more increased in postmenopausal patients with bone metastases. The results reflect an important bone turnover in breast cancer. The data suggest that Dpyr assay seems promising to evaluate the rate of bone loss and the response to treatment in bone metastases.

Adult↗

PubMedDate not supplied

Ineffectiveness of sequential high dose methotrexate and 5-fluorouracil combined with epirubicin (FEMTX regimen) as a salvage therapy in advanced colorectal cancers and other gastrointestinal tumors.

The combination of sequential high dose methotrexate and 5-fluorouracil (FU) combined with epirubicin (FEMTX regimen) has shown some clinical efficiency as a first line therapy in advanced gastric cancer. We evaluated the therapeutic activity of this combination in advanced colorectal cancer patients who failed the FU + folinic acid regimen, and in advanced gastrointestinal cancer situation where no standard regimen is available. Twelve patients with measurable metastatic colorectal cancer refractory to first line (n = 6) or second line (n = 6) chemotherapy, as well as 9 patients with advanced gastrointestinal cancer, entered this pragmatic pilot study. Eighty-six per cent and 38% of the patients experienced severe haematological or non-haematological toxicities, respectively. Four patients were not evaluable for response due to their early departure from the scheme due to acute toxic events (n = 3) or toxic death (n = 1). No objective response was observed, but 9 stabilisations and 8 progressive diseases were noted. The FEMTX regimen is not of clinical value as a salvage therapy in colorectal and gastrointestinal cancer, because of its toxicity and its lack of efficacy.

Adult↗

PubMedDate not supplied

Age as a prognostic factor in breast cancer.

We retrospectively analysed data from 1751 patients with non-metastatic and non-inflammatory breast cancer treated in our institution between 1977 and 1989, in order to evaluate the link between age and prognosis in breast cancer. We chose three age groups (1): < or = 33 (n = 67), 34-40 ( n = 155), > 40 years (n = 1529). There were no significant differences in the distribution of clinical tumor size (T), histological node status (N), histology of the primary-tumor and progesterone receptor levels (PR). Younger patients had a higher proportion of SBR III (p < 0.0001), and of Estradiol Receptor negative tumors (EP). There was a significant difference between the three groups in terms of overall survival (p < 0.035), breast cancer specific survival (p < 0.0001) and relapse-free survival (p < 0.0002). Younger patients had a significantly poorer prognosis (survival and relapse) than older ones. Multivariate analysis of specific survival demonstrated that young age at diagnosis was a poor independent prognostic factor.

Adult↗